Browse studies

Find your next paid study

700 recruiting studies matching your filters

MIND-WELL: A Dyadic Intervention for Lung Cancer Survivors and Family Caregivers During Transition

Lung cancer patients often go through more than one type of treatment, such as chemotherapy, radiation, and immunotherapy. These treatments can lead to several…

Lung Cancer (Diagnosis)CaregiverStress

Estimated

~$10 – $6,250

University of ArizonaNCT07839325

Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108

Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

Lung CancerLung Cancer Stage I

Estimated

~$10 – $750

Memorial Sloan Kettering Cancer CenterNCT06424327

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II,…

Muscle Invasive Bladder Urothelial CarcinomaEsophageal CancerGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma+4 more

Estimated

~$10 – $1,125

Paradigm HealthNCT06605404

Phase 2

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) …

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07063745

Phase 1

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with …

Lung CancerBreast Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06618287

Phase 2

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and p…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT05061550

Phase 3

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in partici…

Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06561386

Phase 1

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in…

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive

Estimated

~$10 – $8,750

Astellas Pharma Global Development, Inc.NCT07140016

Observational

A Pilot Trial of Bright Light Therapy in Patients Receiving First Line Immune Checkpoint Blockade

This study is being done to test whether bright light therapy can be used to synchronize patients' circadian rhythms and allow ICB (immune-checkpoint blockade)…

Melanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT07661966

Phase 2

Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the …

Squamous Cell Lung Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05607108

Phase 3

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doubl…

Non-squamous Non-small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT06627647

Phase 3

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembroliz…

Non-Small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT06357533